Dr. Love,
I remember Dr. Love as CEO of Hyseq speaking about how great their patent estate in genes were going to make the company. At the time they were saying they had IP on about 100,000 genes, five times the number of genes there turns out to be.
With all this great gene discovery and IP they had, they licensed their product from Amgen. Why would Amgen give up this great product?
then he was running his trials and running out of money, and low and behold he is saved by ONXX. Coles was not running ONXX at the time, so they must have become friendly after he joined.
I do not think Love is honest because while he was running his VTE studies he would constantly speak about the drug working in stroke, and that woud be a bigger market. That was never going to happen. The drug has such a short half life that it would have needed to be delivered with a catheter very precisely in the neck. When someone has a stroke, it is hard enough figuring out how long ago they had it, and what to do with them, without having a doctor on staff that would be an expert on delivering this particular drug in the emergency room.
